The Vector Center plans to release the first batch of its coronavirus vaccine in November. The head of the center's laboratory, Ilnaz Imatdinov, spoke about this in the Dok-Tok program on Channel One.
He specified that this will happen after the registration of the vaccine. According to him, the first released series of the drug will be used for extended clinical trials.
Imatdinov noted that the tests showed the presence of the required amount of antibodies to coronavirus in all participants in the trials of this vaccine, and only six out of 100 people complained of pain at the injection site, which subsequently passed by itself.
According to Rospotrebnadzor, the EpiVacCorona vaccine has a high degree of safety, it uses artificially synthesized peptides, rather than fragments of the virus itself.
According to the head of the department Anna Popova, clinical trials of the vaccine developed by the Vector Center will end on September 30, after which post-registration studies will begin.
Earlier it was reported that more than 50 countries showed interest in the Russian vaccine against coronavirus "Sputnik V", created by the Gamaleya Research Center for Electrochemistry and Technology. This drug became the world's first registered vaccine for the prevention of COVID-19.